/ /

  • linkedin
  • Increase Font
  • Sharebar

    Sustained drug delivery moving toward clinical use


    Ocular Therapeutix

    Ocular Therapeutix’s hydrogel sealant, ReSeal, launches in the United States this year. The same hydrogel technology is being developed for sustained release drug delivery.

    “We have an opportunity in glaucoma to do a better drug delivery,” said Scott Corning, vice president of marketing and sales. “Our punctal plug with a prostaglandin analog shows very good IOP lowering at 1 month and 2 months with no hyperemia.”

    The company is launching a phase IIb trial in glaucoma later this year, using a 90-day sustained release plug. Other products in development include a dexamethasone-loaded plug for inflammation and an injectable anti-VEGF depot for 6-month use in wet age-related macular degeneration (AMD) and other retinal conditions.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results